Research analysts at StockNews.com assumed coverage on shares of ReWalk Robotics (NASDAQ:RWLK – Get Free Report) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the medical device company’s stock.
Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of ReWalk Robotics in a research note on Thursday, August 10th.
View Our Latest Research Report on RWLK
ReWalk Robotics Trading Down 1.7 %
ReWalk Robotics (NASDAQ:RWLK – Get Free Report) last announced its quarterly earnings data on Friday, August 11th. The medical device company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. The company had revenue of $1.34 million during the quarter, compared to the consensus estimate of $1.34 million. ReWalk Robotics had a negative return on equity of 27.83% and a negative net margin of 350.43%. Sell-side analysts predict that ReWalk Robotics will post -0.35 earnings per share for the current fiscal year.
Insider Activity
In related news, major shareholder Global Fund Lp Lind II acquired 100,000 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The stock was acquired at an average cost of $0.76 per share, with a total value of $76,000.00. Following the completion of the purchase, the insider now directly owns 4,751,529 shares in the company, valued at $3,611,162.04. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders bought 262,708 shares of company stock valued at $185,224 and sold 35,242 shares valued at $24,317. Insiders own 2.10% of the company’s stock.
Institutional Investors Weigh In On ReWalk Robotics
A number of institutional investors have recently made changes to their positions in RWLK. Renaissance Technologies LLC grew its stake in shares of ReWalk Robotics by 216.1% during the second quarter. Renaissance Technologies LLC now owns 96,400 shares of the medical device company’s stock worth $91,000 after purchasing an additional 65,900 shares during the period. Millennium Management LLC lifted its holdings in ReWalk Robotics by 78.6% during the second quarter. Millennium Management LLC now owns 138,282 shares of the medical device company’s stock worth $130,000 after acquiring an additional 60,859 shares in the last quarter. Finally, Virtu Financial LLC lifted its holdings in ReWalk Robotics by 249.6% during the fourth quarter. Virtu Financial LLC now owns 47,638 shares of the medical device company’s stock worth $36,000 after acquiring an additional 34,013 shares in the last quarter. 3.58% of the stock is owned by institutional investors and hedge funds.
About ReWalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic.
Featured Articles
- Five stocks we like better than ReWalk Robotics
- How Can Investors Benefit From After-Hours Trading
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- How to Invest in Renewable Energy
- 5 Reasons Mullen Automotive is About to Turn a Corner
- How Investors Can Identify and Successfully Trade Gap-Up Stocks
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.